期刊
REDOX BIOLOGY
卷 53, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.redox.2022.102346
关键词
SELENOP; Glutathione peroxidase; Selenium; Prognosis; Cohort study
资金
- Deutsche Forschungsgemeinschaft (DFG), Research Unit FOR-2558 TraceAge [Scho849/6-2]
- CRC/TR 296 Local control of TH action (LocoTact) [P17]
- BIH, Berlin Institute of Health, Berlin, Germany
The presence of SELENOP autoantibodies in breast cancer patients is associated with poor prognosis, particularly in patients with low selenium levels. These autoantibodies may disrupt the transport function of SELENOP, leading to an increased risk of recurrence and mortality.
Background: Low concentrations of serum selenium (Se) and its main transporter selenoprotein P (SELENOP) are associated with a poor prognosis following breast cancer diagnosis. Recently, natural autoantibodies (aAb) with antagonistic properties to SELENOP uptake have been identified in healthy subjects, and in patients with thyroid disease. Given the potential transport disrupting properties, we hypothesized that breast cancer patients with SELENOP-aAb may have a poor prognosis. Methods: SELENOP-aAb along with serum Se, SELENOP and GPX3 activity were determined in serum samples of 1988 patients with a new diagnosis of breast cancer enrolled in the multicentre SCAN-B study. Patients were followed for ~9 years and multivariate Cox regression models were applied to assess hazard ratios. Results: Applying a cut-off based on outlier detection, we identified 7.65% of patients with SELENOP-aAb. Autoantibody titres correlated positively to total Se and SELENOP concentrations, but not to GPX3 activity, supporting a negative role of SELENOP-aAb on Se transport. SELENOP-aAb were associated with age, but in-dependent of tumor characteristics. After fully adjusting for potential confounders, SELENOP-aAb were associated with higher recurrence, HR(95%CI) = 1.87(1.17-2.99), particularly in patients with low Se concentrations, HR(95%CI) = 2.16(1.20-3.88). Associations of SELENOP-aAb with recurrence and mortality were linear and dose-dependent, with fully adjusted HR(95%CI) per log increase of 1.25(1.01-1.55) and 1.31(1.13-1.51), respectively. Conclusion: Our results indicate a prognostic and pathophysiological relevance of SELENOP-aAb in breast cancer, with potential relevance for other malignancies. Assessment of SELENOP-aAb at time of diagnosis identifies patients with a distinctly elevated risk for a poor prognosis, independent of established prognostic factors, who may respond favourably to Se supplementation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据